

Mika Scheinin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1235185/publications.pdf>

Version: 2024-02-01

170
papers

7,215
citations

57758

44
h-index

64796

79
g-index

172
all docs

172
docs citations

172
times ranked

6804
citing authors

#	ARTICLE	IF	CITATIONS
1	Uptake of ¹⁸ F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 205-213.	1.0	3
2	Acute stress effects of impulsive noise during mental work. <i>Journal of Environmental Psychology</i> , 2022, 81, 101819.	5.1	4
3	Safety, Biodistribution, and Radiation Dosimetry of ¹⁸ F-rhPSMA-7.3 in Healthy Adult Volunteers. <i>Journal of Nuclear Medicine</i> , 2021, 62, 679-684.	5.0	20
4	Speech is special: The stress effects of speech, noise, and silence during tasks requiring concentration. <i>Indoor Air</i> , 2021, 31, 264-274.	4.3	14
5	Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 44.	1.6	1
6	Assessing an Electronic Health Record research platform for identification of clinical trial participants. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100692.	1.1	6
7	Kinetic analysis and optimisation of ¹⁸ F-rhPSMA-7.3 PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3723-3731.	6.4	10
8	Nitrogen Balance after the Administration of a Prolonged-Release Protein Substitute for Phenylketonuria as a Single Dose in Healthy Volunteers. <i>Nutrients</i> , 2021, 13, 3189.	4.1	6
9	Effects of remifentanyl on pharyngeal swallowing and esophageal motility: no impact of different bolus volumes and partial antagonism by methylalntrexone. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, G367-G377.	3.4	7
10	Foundations of Human Consciousness: Imaging the Twilight Zone. <i>Journal of Neuroscience</i> , 2021, 41, 1769-1778.	3.6	30
11	Evidence that the multiflorine-derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at β -adrenoceptors in mice. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 290-302.	4.4	3
12	Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients. <i>Anesthesia and Analgesia</i> , 2020, 130, 949-957.	2.2	33
13	Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1467-1482.	3.5	4
14	Effects of intramuscular vatinoxan (MK-467), co-administered with medetomidine and butorphanol, on cardiopulmonary and anaesthetic effects of intravenous ketamine in dogs. <i>Veterinary Anaesthesia and Analgesia</i> , 2020, 47, 604-613.	0.6	3
15	Amino Acid Plasma Profiles from a Prolonged-Release Protein Substitute for Phenylketonuria: A Randomized, Single-Dose, Four-Way Crossover Trial in Healthy Volunteers. <i>Nutrients</i> , 2020, 12, 1653.	4.1	11
16	<i>Candida antarctica</i> Lipase A-Based Enantioselective Recognition of a Highly Strained 4-Dibenzocyclooctynol (DIBO) Used for PET Imaging. <i>Molecules</i> , 2020, 25, 879.	3.8	4
17	Investigation of the effects of vatinoxan on somatic and visceral antinociceptive efficacy of medetomidine in dogs. <i>American Journal of Veterinary Research</i> , 2020, 81, 299-308.	0.6	4
18	Application of the PET ligand [¹¹ C]ORM-13070 to examine receptor occupancy by the β -adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. <i>EJNMMI Research</i> , 2020, 10, 152.	2.5	4

#	ARTICLE	IF	CITATIONS
19	Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression. <i>EBioMedicine</i> , 2019, 47, 170-183.	6.1	41
20	Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 948-959.	8.1	65
21	Cardiovascular and sedation reversal effects of intramuscular administration of atipamezole in dogs treated with medetomidine hydrochloride with or without the peripheral α_2 -adrenoceptor antagonist vinoxan hydrochloride. <i>American Journal of Veterinary Research</i> , 2019, 80, 912-922.	0.6	6
22	Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. <i>Neuropsychopharmacology</i> , 2019, 44, 1667-1673.	5.4	33
23	Radiosynthesis and Preclinical Evaluation of an α_2 -Adrenoceptor Tracer Candidate, 6-[¹⁸ F]Fluoro-marsanidine. <i>Molecular Imaging and Biology</i> , 2019, 21, 879-887.	2.6	4
24	Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study. <i>BMC Anesthesiology</i> , 2019, 19, 22.	1.8	7
25	Treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes. <i>BMJ Open</i> , 2019, 9, e023728.	1.9	4
26	Pharmacodynamic and pharmacokinetic profile of SM-0951, a triple-drug combination to increase total sleep time. <i>Human Psychopharmacology</i> , 2019, 34, e2716.	1.5	1
27	Upper Airway Collapsibility during Dexmedetomidine and Propofol Sedation in Healthy Volunteers. <i>Anesthesiology</i> , 2019, 131, 962-973.	2.5	39
28	Peripheral α_2 -adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. <i>Veterinary Anaesthesia and Analgesia</i> , 2018, 45, 405-413.	0.6	12
29	Sedative Plasma Concentrations and Delirium Risk in Critical Illness. <i>Annals of Pharmacotherapy</i> , 2018, 52, 513-521.	1.9	13
30	Effect of oral KETOPROFEN treatment in acute respiratory disease outbreaks in finishing pigs. <i>Porcine Health Management</i> , 2018, 4, 7.	2.6	1
31	Effects of the peripherally acting α_2 -adrenoceptor antagonist MK-467 on cardiopulmonary function in sheep sedated by intramuscular administration of medetomidine and ketamine and reversed by intramuscular administration of atipamezole. <i>American Journal of Veterinary Research</i> , 2018, 79, 921-932.	0.6	10
32	Increased Energy Expenditure, Lipolysis and Hyperinsulinemia Confer Resistance to Central Obesity and Type 2 Diabetes in Mice Lacking Alpha2-Adrenoceptors. <i>Neuroendocrinology</i> , 2018, 107, 324-339.	2.5	6
33	Plasma concentration and cardiovascular effects of intramuscular medetomidine combined with three doses of the peripheral alpha2-antagonist MK-467 in dogs. <i>Veterinary Anaesthesia and Analgesia</i> , 2017, 44, 417-426.	0.6	23
34	Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor-Like 1 (ORL1) Partial Agonist, in Patients With Isolated Systolic Hypertension. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 584-591.	1.6	12
35	Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 1-9.	3.7	17
36	Cardiovascular effects of premedication with medetomidine alone and in combination with MK-467 or glycopyrrolate in dogs subsequently anesthetized with isoflurane. <i>American Journal of Veterinary Research</i> , 2017, 78, 1245-1254.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Effects of the α_2 -adrenoceptor agonist medetomidine on the distribution and clearance of alfaxalone during coadministration by constant rate infusion in dogs. <i>American Journal of Veterinary Research</i> , 2017, 78, 956-964.	0.6	13
38	Gene expression profiles and signaling mechanisms in α_2 -adrenoceptor-evoked proliferation of vascular smooth muscle cells. <i>BMC Systems Biology</i> , 2017, 11, 65.	3.0	15
39	The effect of an apple polyphenol extract rich in epicatechin and flavan-3-ol oligomers on brachial artery flow-mediated vasodilatory function in volunteers with elevated blood pressure. <i>Nutrition Journal</i> , 2017, 16, 73.	3.4	22
40	The role of active transport in the transcellular movement of the peripheral α_2 -adrenoceptor antagonist, MK-467: An pilot study. <i>Canadian Journal of Veterinary Research</i> , 2017, 81, 318-320.	0.2	0
41	Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the α_2 -adrenoceptor PET ligand [11 C]ORM-13070. <i>Synapse</i> , 2016, 70, 57-65.	1.2	10
42	Clinical effects and pharmacokinetic variables of romifidine and the peripheral α_2 -adrenoceptor antagonist MK-467 in horses. <i>Veterinary Anaesthesia and Analgesia</i> , 2016, 43, 599-610.	0.6	33
43	Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial. <i>EBioMedicine</i> , 2016, 13, 190-200.	6.1	108
44	Sedation with Dexmedetomidine or Propofol Impairs Hypoxic Control of Breathing in Healthy Male Volunteers. <i>Anesthesiology</i> , 2016, 125, 700-715.	2.5	52
45	A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3174-3183.	3.0	15
46	Differential Internalization Rates and Postendocytic Sorting of the Norepinephrine and Dopamine Transporters Are Controlled by Structural Elements in the N Termini. <i>Journal of Biological Chemistry</i> , 2016, 291, 5634-5651.	3.4	15
47	Transfer of SAR information from hypotensive indazole to indole derivatives acting at α_2 -adrenergic receptors: In vitro and in vivo studies. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 406-415.	5.5	14
48	Imaging of α_2 -adrenoceptors in the living brain: a method to monitor noradrenaline release?. <i>SpringerPlus</i> , 2015, 4, L20.	1.2	0
49	Potential of Glibenclamide Hypoglycaemia in Mice by MK-467, a Peripherally Acting α_2 -Adrenoceptor Antagonist. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 392-398.	2.5	4
50	Amphetamine Decreases α_2 -Adrenoceptor Binding of [11 C]ORM-13070: A PET Study in the Primate Brain. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu081-pyu081.	2.1	13
51	Validation of [11 C]ORM-13070 as a PET tracer for α_2 -adrenoceptors in the human brain. <i>Synapse</i> , 2015, 69, 172-181.	1.2	14
52	Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 321-327.	1.9	30
53	Detomidine and the combination of detomidine and MK-467, a peripheral α_2 adrenoceptor antagonist, as premedication in horses anaesthetized with isoflurane. <i>Veterinary Anaesthesia and Analgesia</i> , 2015, 42, 527-536.	0.6	25
54	Test-retest reliability of 11 C-ORM-13070 in PET imaging of α_2 -adrenoceptors in vivo in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 120-127.	6.4	130

#	ARTICLE	IF	CITATIONS
55	Comparison of simultaneous measurement of mouse locomotor activity by radiotelemetry and photobeam methods. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 71, 90-94.	0.7	1
56	Sensitivity of [¹¹ C]ORM-13070 to increased extracellular noradrenaline in the CNS – a PET study in human subjects. <i>Psychopharmacology</i> , 2015, 232, 4169-4178.	3.1	12
57	Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1197-1207.	1.9	42
58	Application of cross-species PET imaging to assess neurotransmitter release in brain. <i>Psychopharmacology</i> , 2015, 232, 4129-4157.	3.1	61
59	A PET Tracer for Brain α_2 Adrenoceptors, ¹¹ C-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1171-1177.	5.0	21
60	Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. <i>Veterinary Anaesthesia and Analgesia</i> , 2014, 41, 372-377.	0.6	12
61	Fluorinated analogues of marsanidine, a highly α_2 -AR/imidazoline 11 binding site-selective hypotensive agent. Synthesis and biological activities. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 386-397.	5.5	14
62	Quantitative determination of α_2 -adrenoceptor-evoked myosin light chain phosphorylation in vascular smooth muscle cells. <i>Journal of Pharmacological and Toxicological Methods</i> , 2014, 70, 152-162.	0.7	4
63	In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [¹⁸ F]flutemetamol. <i>EJNMMI Research</i> , 2014, 4, 37.	2.5	22
64	¹¹ C-ORM-13070, a novel PET ligand for brain α_2 -adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1947-1956.	6.4	16
65	Reply to –Letter to the editor: –Deconstructing the dogma of sympathetic restraint and its role in the cardiovascular response to exercise– American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H464-H464.	3.2	0
66	Rifampicin markedly decreases the exposure to oral and intravenous tramadol. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1293-1301.	1.9	25
67	Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 867-875.	1.9	15
68	Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 387-395.	1.9	10
69	Inhibition of α_2 -adrenergic tone disturbs the distribution of blood flow in the exercising human limb. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H163-H172.	3.2	47
70	Variation in the α_2A adrenoceptor gene and the effect of dexmedetomidine on plasma insulin and glucose. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 479-486.	1.5	13
71	Longitudinal Amyloid Imaging in Mouse Brain with ¹¹ C-PIB: Comparison of APP23, Tg2576, and APP ^{swe} -PS1 ^{dE9} Mouse Models of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1434-1441.	5.0	71
72	Plasma drug concentrations and clinical effects of a peripheral alpha-2-adrenoceptor antagonist, MK-467, in horses sedated with detomidine. <i>Veterinary Anaesthesia and Analgesia</i> , 2013, 40, 257-264.	0.6	42

#	ARTICLE	IF	CITATIONS
73	A polymorphism in the protein kinase C gene PRKCB is associated with α_2 -adrenoceptor-mediated vasoconstriction. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 127-134.	1.5	5
74	Effects of Ospemifene on Drug Metabolism Mediated by Cytochrome P450 Enzymes in Humans in Vitro and in Vivo. <i>International Journal of Molecular Sciences</i> , 2013, 14, 14064-14075.	4.1	9
75	Oral bioavailability of ospemifene improves with food intake. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 787-794.	0.6	9
76	Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 861-867.	0.6	9
77	Influence of MK-467, a Peripherally Acting α_2 -Adrenoceptor Antagonist on the Disposition of Intravenous Dexmedetomidine in Dogs. <i>Drug Metabolism and Disposition</i> , 2012, 40, 445-449.	3.3	49
78	Involvement of α_2 -Adrenoceptor Subtypes A and C in Glucose Homeostasis and Adrenaline-Induced Hyperglycaemia. <i>Neuroendocrinology</i> , 2012, 96, 51-59.	2.5	15
79	High-throughput screening with a miniaturized radioligand competition assay identifies new modulators of human α_2 -adrenoceptors. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 941-951.	4.0	8
80	Pharmacokinetics of [18 F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1784-1795.	6.4	52
81	CYP2A6 genetic variation and dexmedetomidine disposition. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 937-942.	1.9	42
82	Synthesis and biological activities of 2-[(heteroaryl)methyl]imidazolines. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 108-116.	3.0	11
83	Might the observed α_2 -adrenoceptor agonism or antagonism of allyphenylene analogues be ascribed to different molecular conformations?. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2082-2090.	3.0	9
84	Different Metabolic Responses of Human Brown Adipose Tissue to Activation by Cold and Insulin. <i>Cell Metabolism</i> , 2011, 14, 272-279.	16.2	609
85	α_2 -Adrenoceptor Regulation of Blood Glucose Homeostasis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 365-370.	2.5	114
86	Dorsal hand vein responses to the α_1 -adrenoceptor agonist phenylephrine do not predict responses to the α_2 -adrenoceptor agonist dexmedetomidine. <i>European Journal of Pharmacology</i> , 2011, 653, 70-74.	3.5	6
87	Bioavailability of dexmedetomidine after intranasal administration. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 825-831.	1.9	159
88	3-[(Imidazolidin-2-yl)imino]indazole ligands with selectivity for the α_2 -adrenoceptor compared to the imidazoline I1 receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 321-329.	3.0	18
89	Genetic Variations in the α_2 -Adrenoceptor Are Associated With Blood Pressure Response to the Agonist Dexmedetomidine. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 179-187.	5.1	27
90	Dietary sodium modulates the interaction between efferent and afferent renal nerve activity by altering activation of α_2 -adrenoceptors on renal sensory nerves. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2011, 300, R298-R310.	1.8	22

#	ARTICLE	IF	CITATIONS
91	Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2011, 55, 265-79.	0.7	6
92	Identification of a novel 12-nucleotide insertion polymorphism in the promoter region of ADRA2B: Full linkage with the 9-nucleotide deletion in the coding region and influence on transcriptional activity. Biochemical Pharmacology, 2010, 79, 407-412.	4.4	9
93	Effects of variation in the human α_2A and α_2C adrenoceptor genes on cognitive tasks and pain perception. European Journal of Pain, 2010, 14, 154-159.	2.8	29
94	Antinociceptive Synergism of MD-354 and Clonidine. Part II. The α_2 Adrenoceptor Component. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 690-697.	2.5	4
95	Homogeneous GTP Binding Assay Employing QRET Technology. Journal of Biomolecular Screening, 2010, 15, 261-267.	2.6	11
96	Octopamine Receptors from the Barnacle Balanus improvisus Are Activated by the α_2 -Adrenoceptor Agonist Medetomidine. Molecular Pharmacology, 2010, 78, 237-248.	2.3	60
97	Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in α_2A -adrenoceptor knockout mice. European Journal of Pharmacology, 2008, 578, 359-364.	3.5	38
98	Expression and characterization of the human α_2B -adrenoceptor in a vascular smooth muscle cell line. European Journal of Pharmacology, 2008, 587, 48-56.	3.5	7
99	Blood pressure regulation and cardiac autonomic control in mice overexpressing α_1 - and α_3 -melanocyte stimulating hormone. Peptides, 2008, 29, 1943-1952.	2.4	11
100	α_2 -Adrenoreceptors Profile Modulation. 4. From Antagonist to Agonist Behavior. Journal of Medicinal Chemistry, 2008, 51, 4289-4299.	6.4	18
101	Ethnic and Genetic Determinants of Cardiovascular Response to the Selective α_2 -Adrenoceptor Agonist Dexmedetomidine. Hypertension, 2008, 51, 406-411.	2.7	37
102	Effects of Low and High Plasma Concentrations of Dexmedetomidine on Myocardial Perfusion and Cardiac Function in Healthy Male Subjects. Anesthesiology, 2006, 105, 902-910.	2.5	108
103	Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction. Pharmacogenetics and Genomics, 2005, 15, 357-363.	1.5	17
104	Effect of α_2B -Adrenoceptor Polymorphism on Peripheral Vasoconstriction in Healthy Volunteers. Anesthesiology, 2005, 102, 536-542.	2.5	28
105	Expression and function of alpha2-adrenoceptors in zebrafish: drug effects, mRNA and receptor distributions. Journal of Neurochemistry, 2005, 94, 1559-1569.	3.9	71
106	Conserved structural, pharmacological and functional properties among the three human and five zebrafish α_2 -adrenoceptors. British Journal of Pharmacology, 2005, 144, 165-177.	5.4	60
107	Intracellularly Truncated Human α_2B -Adrenoceptors: Stable and Functional GPCRs for Structural Studies. Journal of Receptor and Signal Transduction Research, 2005, 25, 99-124.	2.5	3
108	Model structures of α_2 -adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands. Journal of Structural Biology, 2005, 150, 126-143.	2.8	30

#	ARTICLE	IF	CITATIONS
109	Neurochemical and behavioural changes in zebrafish <i>Danio rerio</i> after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Journal of Neurochemistry</i> , 2004, 88, 443-453.		186
110	Identification of Duplicated Fourth β -Adrenergic Receptor Subtype by Cloning and Mapping of Five Receptor Genes in Zebrafish. <i>Molecular Biology and Evolution</i> , 2004, 21, 14-28.	8.9	56
111	Loss of amitriptyline analgesia in β 2A-adrenoceptor deficient mice. <i>European Journal of Pharmacology</i> , 2004, 485, 193-196.	3.5	27
112	[Ethyl-3H]RS-79948-197 β 2-adrenoceptor autoradiography validation in β 2-adrenoceptor knockout mice. <i>European Journal of Pharmacology</i> , 2004, 497, 301-309.	3.5	13
113	Altered glucose homeostasis in β 2A-adrenoceptor knockout mice. <i>European Journal of Pharmacology</i> , 2004, 505, 243-252.	3.5	47
114	Cloning, characterisation and identification of several polymorphisms in the promoter region of the human β 2B-adrenergic receptor gene. <i>Biochemical Pharmacology</i> , 2004, 67, 469-478.	4.4	15
115	Ligand-induced β 2-adrenoceptor endocytosis: relationship to Gi protein activation. <i>Biochemical and Biophysical Research Communications</i> , 2004, 321, 226-233.	2.1	24
116	Agonist-dependent trafficking of β 2-adrenoceptor subtypes: dependence on receptor subtype and employed agonist. <i>European Journal of Cell Biology</i> , 2003, 82, 231-239.	3.6	18
117	Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the β 2A-adrenoceptor. <i>British Journal of Pharmacology</i> , 2003, 140, 347-358.	5.4	28
118	Nonradioactive GTP Binding Assay to Monitor Activation of G Protein-Coupled Receptors. <i>Assay and Drug Development Technologies</i> , 2003, 1, 275-280.	1.2	56
119	Variation in the α 2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. <i>Journal of the American College of Cardiology</i> , 2003, 41, 190-194.	2.8	97
120	Functional expression and direct visualization of the human β 2B-adrenergic receptor and β 2B-AR-green fluorescent fusion protein in mammalian cell using Semliki Forest virus vectors. <i>Protein Expression and Purification</i> , 2003, 32, 265-275.	1.3	20
121	Constitutive precoupling to Gi and increased agonist potency in the β 2B-adrenoceptor. <i>Biochemical and Biophysical Research Communications</i> , 2003, 306, 959-965.	2.1	12
122	β 2B-Adrenoceptor levels govern agonist and inverse agonist responses in PC12 cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 308, 12-18.	2.1	6
123	β 2-Adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the β 2A-adrenoceptor subtype. <i>Neuropharmacology</i> , 2003, 44, 882-892.	4.1	91
124	Effects of common polymorphisms in the β 1A-, β 2B-, β 21- and β 22-adrenoreceptors on haemodynamic responses to adrenaline. <i>Clinical Science</i> , 2003, 104, 509-520.	4.3	69
125	α 2C-adrenoceptor mediated regulation of cortical EEG arousal. <i>Neuropharmacology</i> , 2002, 43, 1305-1312.	4.1	14
126	An insertion/deletion polymorphism in the β 2b-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1516-1522.	2.8	110

#	ARTICLE	IF	CITATIONS
127	Molecular Mechanism for Agonist-Promoted α_2 -Adrenoceptor Activation by Norepinephrine and Epinephrine. <i>Molecular Pharmacology</i> , 2001, 59, 1343-1354.	2.3	59
128	Phenoxybenzamine Binding Reveals the Helical Orientation of the Third Transmembrane Domain of Adrenergic Receptors. <i>Journal of Biological Chemistry</i> , 2001, 276, 31279-31284.	3.4	34
129	Influence of hydroxychloroquine on the bioavailability of oral metoprolol. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 549-554.	2.4	89
130	Title is missing!. <i>Biotechnology Letters</i> , 2000, 22, 1963-1966.	2.2	0
131	Receptor Subtype-Induced Targeting and Subtype-Specific Internalization of Human α_2 -Adrenoceptors in PC12 Cells. <i>Journal of Neuroscience</i> , 1999, 19, 9281-9288.	3.6	51
132	Identification of a Three-Amino Acid Deletion in the α_2 -Adrenergic Receptor That Is Associated with Reduced Basal Metabolic Rate in Obese Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2429-2433.	3.6	103
133	Chloroethylclonidine and 2-Aminoethyl Methanethiosulfonate Recognize Two Different Conformations of the Human α_2 -Adrenergic Receptor. <i>Journal of Biological Chemistry</i> , 1999, 274, 21867-21872.	3.4	33
134	Three-dimensional Models of α_2 -Adrenergic Receptor Complexes Provide a Structural Explanation for Ligand Binding. <i>Journal of Biological Chemistry</i> , 1999, 274, 23405-23413.	3.4	31
135	Non-adrenergic binding of [³ H]atipamezole in rat kidney-regional distribution and comparison to α_2 -adrenoceptors. <i>British Journal of Pharmacology</i> , 1999, 128, 1215-1222.	5.4	9
136	α_2 -Adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. <i>European Journal of Pharmacology</i> , 1999, 374, 137-146.	3.5	22
137	Functional assessment of recombinant human α_2 -adrenoceptor subtypes with Cytosensor microphysiometry. <i>European Journal of Pharmacology</i> , 1999, 385, 247-253.	3.5	23
138	The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers. , 1999, 20, 327-334.		12
139	PET in drug discovery and development: an introduction. <i>Annals of Medicine</i> , 1999, 31, 430-431.	3.8	4
140	Subtype-specific stimulation of [³ H]GTP γ S binding by recombinant α_2 -adrenoceptors. <i>European Journal of Pharmacology</i> , 1998, 355, 275-279.	3.5	46
141	Adrenergic α_2 -Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice. <i>Journal of Neuroscience</i> , 1998, 18, 3035-3042.	3.6	166
142	Chloroethylclonidine Binds Irreversibly to Exposed Cysteines in the Fifth Membrane-Spanning Domain of the Human α_2 -Adrenergic Receptor. <i>Molecular Pharmacology</i> , 1998, 53, 370-376.	2.3	32
143	Antenatal Dexamethasone Treatment Decreases Plasma Catecholamine Levels in Preterm Infants. <i>Pediatric Research</i> , 1998, 43, 801-807.	2.3	16
144	Postoperative Pharmacokinetics and Sympatholytic Effects of Dexmedetomidine. <i>Anesthesia and Analgesia</i> , 1997, 85, 1136-1142.	2.2	80

#	ARTICLE	IF	CITATIONS
145	Postoperative Pharmacokinetics and Sympatholytic Effects of Dexmedetomidine. <i>Anesthesia and Analgesia</i> , 1997, 85, 1136-1142.	2.2	247
146	Genetic Alteration of α_2 -Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedetomidine, a Subtype-Nonselective α_2 -Adrenoceptor Agonist. <i>Molecular Pharmacology</i> , 1997, 51, 36-46.	2.3	149
147	α_2 -Adrenoceptor regulation of adenylyl cyclase in CHO cells: Dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. <i>European Journal of Pharmacology</i> , 1997, 335, 53-63.	3.5	78
148	Assessment of α_2 -adrenoceptor antagonist potency with GTPase assay. <i>European Journal of Pharmacology</i> , 1997, 338, 293-296.	3.5	5
149	Gene targeting "homing in on α_2 -adrenoceptor-subtype function. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 211-219.	8.7	298
150	Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 450-457.	4.7	32
151	The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 221-227.	4.7	24
152	Molecular Pharmacology of α_2 -adrenoceptor Subtypes. <i>Annals of Medicine</i> , 1995, 27, 439-449.	3.8	100
153	Recombinant human α_2 -adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 as radioligands. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995, 1266, 207-214.	4.1	62
154	Molecular Pharmacology of α_2 -adrenoceptor Subtypes. <i>Annals of Medicine</i> , 1995, 27, 439-449.	3.8	41
155	Coupling of human α_2 -adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells. <i>European Journal of Pharmacology</i> , 1994, 266, 165-174.	2.6	68
156	Distribution of α_2 -adrenergic receptor subtype gene expression in rat brain. <i>Molecular Brain Research</i> , 1994, 21, 133-149.	2.3	398
157	Reduced Turnover of Dopamine and 5-Hydroxytryptamine in Discrete Dopaminergic, Noradrenergic and Serotonergic Rat Brain Areas after Acutely Administered Medetomidine, a Selective α_2 -Adrenoceptor Agonist. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993, 72, 182-187.	0.0	16
158	Cloning and expression of a fish α_2 -adrenoceptor. <i>British Journal of Pharmacology</i> , 1993, 110, 54-60.	5.4	38
159	Stable expression of recombinant human α_2 -adrenoceptor subtypes in two mammalian cell lines: characterization with [3H]rauwolscine binding, inhibition of adenylate cyclase and RNase protection assay. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1134, 169-177.	4.1	25
160	Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 537-546.	4.7	64
161	Plasma 3, 4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4- hydroxyphenylglycol (MHPG) are insensitive indicators of α_2 -adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. <i>Life Sciences</i> , 1991, 49, 75-84.	4.3	88
162	Detomidine Reduces the Plasma Catecholamine, but not Cortisol Concentrations in Horses. <i>Transboundary and Emerging Diseases</i> , 1991, 38, 153-156.	0.6	19

#	ARTICLE	IF	CITATIONS
163	Dexmedetomidine, an α_2 -Adrenoceptor Agonist, Reduces Anesthetic Requirements for Patients Undergoing Minor Gynecologic Surgery. <i>Anesthesiology</i> , 1990, 73, 230-235.	2.5	256
164	Hormonal, Haemodynamic, and Subjective Effects of Intravenously Infused Indomethacin: No Change in the Physiological Response to Hypertonic Saline Challenge. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1989, 65, 231-235.	0.0	3
165	Effects of dexmedetomidine, a selective α_2 -adrenoceptor agonist, on hemodynamic control mechanisms. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 33-42.	4.7	203
166	Behavioural and neurochemical effects of antipamezole, a novel α_2 -adrenoceptor antagonist. <i>European Journal of Pharmacology</i> , 1988, 151, 35-42.	3.5	112
167	Placental and Blood-CSF Transfer of Intramuscularly Administered Atropine in the same Person. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1987, 60, 108-109.	0.0	7
168	Monoamine Metabolite Levels in Rat CSF: Kinetic Studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1987, 61, 167-171.	0.0	2
169	Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 261-267.	4.7	34
170	Determination of Conjugated Dopamine in Cerebrospinal Fluid from Humans and Non-human Primates with High Performance Liquid Chromatography using Electrochemical Detection. <i>Acta Pharmacologica Et Toxicologica</i> , 1984, 55, 88-94.	0.0	18